| 摘要 |
The invention is directed to novel inhibitors of CDK4/6 of formula (I)wherein R, R, R, R-R, A and L are defined herein and to pharmaceutically acceptable salts thereof. The invention is further directed to pharmaceutical compositions comprising said compound and pharmaceutically acceptable carrier or inert excipient. The invention further relates to methods for the treatment of cancer comprising administering an effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof to a patient, where cancer is selected from the group including mantle cell lymphoma, multiple myeloma, breast cancer, squamous cell esophageal cancer, melanoma, non small cell lung cancer, colon cancer and pancreatic cancer. |
